Global Kidney Cancer Diagnostics Market to Flourish at a 7% CAGR By 2032; Immunohistochemistry-based Diagnostics to Comprise 65% of Total Usage | Fact.MR


<!– Name:DistributionId Value:8830948 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value:2791 –> <!– Name:CustomerId Value:1107685 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:559ec07c-4279-4ac3-947d-2b7278b60033 –>

Rockville, May 03, 2023 (GLOBE NEWSWIRE) — Fact.MR – A Market Research and Competitive Intelligence Provider: During the forecast period 2022-2032, the kidney cancer diagnostics market is expected to grow at a value of 7% CAGR, according to Fact.MR. By the year 2032, the global kidney cancer diagnostics market share is expected to rise up to a market valuation of US$ 1.4 Billion. The process of finding biomarkers, enzymes, and other indicators that can be utilized to diagnose a malignant tumor is known as cancer diagnostics.

Diagnostic testing is used to confirm or rule out sickness, track disease development, and plan and evaluate treatment outcomes. Imaging, laboratory tests (including tumor marker tests), tumor biopsy, endoscopic examination, genetic testing, and surgery are all cancer diagnostic methods.

For more insights into the Market, Request a Sample of this Report –

The market is being driven primarily by an increase in the prevalence of kidney cancer and increased R&D investment by pharmaceutical companies. According to a study issued in July 2021 by the International Kidney Cancer Coalition, kidney cancer affects approximately 431,000 people globally each year. Demand for renal cancer therapeutics and diagnostics is expected to grow over the projected period as the prevalence of kidney cancer rises.

Increased public and government healthcare spending, as well as rising demand for kidney cancer molecular diagnostics, are propelling the market ahead. Improved versions of well-known diagnostic tools will almost certainly succeed them. Governments all around the globe are launching numerous programmes to improve kidney cancer detection systems, with a focus on R&D.

The great majority of kidney cancer cases are detected late in the disease’s progression. Even if the prognosis is just marginally better, the severity of cancer and its diagnosis impact patients’ and physicians’ willingness to pay the high cost of therapy. The worldwide cancer diagnostics market may experience challenges over the forecast period due to poor clinical trial success rates and expensive expenses. Such occurrences, if repeated within the projection period, have the potential to stifle progress.

Key Takeaways from the Market Study

  • In 2022, the global kidney cancer diagnostics market is estimated to have a global market size of US$ 800 Million
  • In 2022, immunohistochemistry by test type is expected to occupy a 65% market share
  • The hospital-associated labs segment is projected to hold a global market share of 40% in 2022.
  • The U.S market for kidney cancer diagnostics is predicted to acquire 35% of the global market share in 2022.
  • The Chinese region is forecast to have a CAGR of 5.8% over the projection period of 2022- 2032.

Share Your Requirements & Get Customized Report –

Competitive Landscape
Manufacturers of kidney cancer diagnostic technologies are working with local health ministries and medical administrations to assess the impact of treatment diagnosis on patients with kidney cancer. Medical organizations and global pharmaceutical sector leaders are redoubling their efforts to develop better kidney cancer diagnostics. Product innovation and ongoing R&D activities to develop advanced technologies have aided market growth.

  • In February 2021, Glenmark Pharma released SUTIB, a generic kidney cancer drug, in India. Sunitinib, an oral MKI, is beneficial in treating patients with gastrointestinal stromal tumors and advanced renal cell carcinoma. Sunitinib is an MKI that is taken orally and works by blocking various enzymes that promote cell growth.
  • Cabolong, an authorized generic of Cabozantinib, was introduced by MSN Labs in September 2021 for the treatment of renal cell cancer. Cabolong is manufactured at MSN Labs’ facility, which has been approved by stringent global regulatory bodies such as the US FDA and EU GMP.

Major Key Players:

  • Myriad Genetics Inc.
  • NeoGenomics Laboratories
  • NanoString Technologies Inc.
  • Sysmex Corporation
  • Rosetta Genomics
  • Illumina Inc.
  • Glenmark
  • Cobolong
  • Quest Diagnostics Incorporated
  • Roche Holding AG

Key Segments Profiled in the Kidney Cancer Diagnostics Market Study

  • By Test :
    • Immunohistochemistry
    • Complete Blood Count
    • Urine Test
    • Blood Chemistry
  • By Indication :
    • Renal Cell Carcinoma
    • Transitional Cell Carcinoma
    • Kidney Sarcoma
    • Wilms Tumor
    • Kidney Lymphoma
  • By End User :
    • Hospital-associated Labs
    • Independent Diagnostic Laboratories
    • Cancer Research Institutes
    • Others
  • By Region :
    • North America
    • Latin America
    • Europe
    • Japan
    • APEJ
    • Middle East Africa

Quick Buy: Kidney Cancer Diagnostics Market Report
Key Questions Covered in the Kidney Cancer Diagnostics Market Report

  • What is the projected value of the Kidney Cancer Diagnostics factors Industry in 2022?
  • At what rate will the global Kidney Cancer Diagnostics factors market size grow until 2032?
  • Which are the factors hampering the growth of Kidney Cancer Diagnostics factors?
  • Which region is expected to lead in the global Kidney Cancer Diagnostics factors market By 2032?
  • Which are the factors driving the Kidney Cancer Diagnostics factors during the forecast period?
  • What is the expected market value of the Kidney Cancer Diagnostics factors market during the forecast period?

Check out more related studies published by Fact.MR Research:

Kidney Dialysis Equipment and Supplies Market Size: Global kidney dialysis equipment sales are valued at around US$ 21 billion in 2022. The kidney dialysis equipment and supplies market is projected to register 5% CAGR and top a valuation of US$ 26 billion by the end of 2026.

Cancer Biomarkers Market Analysis: The market for cancer biomarkers is expected to exceed US$ 34 Billion by 2032, representing a threefold increase from 2022. The market is currently worth slightly more than US$ 11 Billion.

Cancer Therapeutics Market Insights: The global cancer therapeutics market is estimated at USD 12.1 Billion in 2022 and is forecast to surpass USD 28.3 Billion by 2032, growing at a CAGR of 8.8% from 2022 to 2032.

Blood Cancer Diagnostics Market: A new report on the blood cancer diagnostics market by Fact.MR provides in-depth analysis of the growth scope, demand-supply patterns, and new trends for the forecast period of 2022 to 2032.

Kidney Stone Management Devices Market Size: Kidney stones are hard deposits of minerals caused by a high concentration of elements such as phosphate, uric acid, calcium, etc. Kidney stones can cause severe discomfort and pain while passing through the urinary tract; they don’t cause any permanent damage except in rare cases.

Artificial Kidney Market: The global artificial kidney market is valued at US$ 1.5 billion in 2023 and is predicted to surge ahead at a CAGR of 13% to reach a market size of US$ 5.3 billion by the end of 2033.

About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Connect to Author: Mr. Shambhu Nath Jha
Email: [email protected]  
Sales Team: [email protected]

Follow Us: LinkedIn | Twitter | YouTube